RBC Capital Remains Bullish on Pacira Pharmaceuticals (PCRX) Following Earnings: 'We expect improving sales trends to continue'
Tweet Send to a Friend
RBC Capital analyst Daniel Busb reiterated an Outperform rating and $81.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
